VYNE pauses VYN202 psoriasis trial after FDA clinical hold tied to animal toxicity data; separate vitiligo trial remains on ...

Studies involving multiple aspects of plaque psoriasis evolution, persistence, and progression have produced clues and ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Deucravacitinib has been observed as a safe and efficacious treatment for adults with moderate to severe plaque psoriasis for up to 4 years.

Icotrokinra appears to be an effective treatment for adolescent patients with moderate to severe plaque psoriasis, according to a subgroup analysis of the ICONIC-LEAD study. The randomized, ...

The hold, placed by the FDA on an early-stage clinical trial of an experimental BET inhibitor, stems from a recent ...

Substantial savings opportunities exist by using lower-cost biologics for patients with plaque psoriasis, according to one ...

Art Garfunkel discusses his experience living with psoriasis as part of Sun Pharma’s I LUV YA for The Long Haul campaign.

The following is a summary of “Treatment of plaque psoriasis with guselkumab reduces systemic inflammatory burden as measured by neutrophil/lymphocyte ratio, platelet/lymphocyte ratio and ...